Helei Y. Hou

16 Jiangsu Road
Qingdao, 266000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 76 publications

SMARCA4 deficiency contributes to platinum resistance in non-small cell lung cancer by activating the NF-κB-BIRC2/BIRC3 signaling axis.

SMARCA4 deficiency contributes to platinum resistance in non-small cell lung cancer by activating the NF-κB-BIRC2/BIRC3 signaling axis.

Journal: Journal of thoracic disease

Published: March 09, 2026

Nuclear PD-L1: an emerging oncogenic driver and promising therapeutic target in cancer.

Nuclear PD-L1: an emerging oncogenic driver and promising therapeutic target in cancer.

Journal: Journal of biomedical science

Published: March 05, 2026

Efficacy and safety of neoadjuvant treatment with chemotherapy and immune checkpoint blockades for potentially resectable gastric cancer: A retrospective study.

Efficacy and safety of neoadjuvant treatment with chemotherapy and immune checkpoint blockades for potentially resectable gastric cancer: A retrospective study.

Journal: Human vaccines & immunotherapeutics

Published: January 08, 2026

A case report: Achieving complete response in synchronous primary lung and tongue squamous cell carcinomas through the integration of albumin-bound paclitaxel, cisplatin, and tislelizumab.

A case report: Achieving complete response in synchronous primary lung and tongue squamous cell carcinomas through the integration of albumin-bound paclitaxel, cisplatin, and tislelizumab.

Journal: Human vaccines & immunotherapeutics

Published: December 05, 2025

Chicoric acid targets PYGL to normalize glycogenolysis-driven glycolysis to suppress non-small cell lung cancer.

Chicoric acid targets PYGL to normalize glycogenolysis-driven glycolysis to suppress non-small cell lung cancer.

Journal: Cellular & molecular biology letters

Published: November 25, 2025

Predicting cardiovascular toxicity in anti-PD-1/PD-L1 therapy: a risk factor analysis and model development.

Predicting cardiovascular toxicity in anti-PD-1/PD-L1 therapy: a risk factor analysis and model development.

Journal: Frontiers in cardiovascular medicine

Published: October 26, 2025

Next-generation sequencing identifies potential mechanisms of primary resistance to trastuzumab-containing therapies in HER2-positive gastric cancer: Analysis based on real-world data and online databases.

Next-generation sequencing identifies potential mechanisms of primary resistance to trastuzumab-containing therapies in HER2-positive gastric cancer: Analysis based on real-world data and online databases.

Journal: Human vaccines & immunotherapeutics

Published: September 09, 2025

ARID1A regulates colorectal cancer metastasis through the AKT/mTOR/p70S6K pathway.

ARID1A regulates colorectal cancer metastasis through the AKT/mTOR/p70S6K pathway.

Journal: Translational oncology

Published: May 26, 2025

Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IVB HER2-positive gastric cancer.

Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IVB HER2-positive gastric cancer.

Journal: Frontiers in immunology

Published: May 08, 2025

Retrospective analysis of clinical characteristics and treatment of patients with immune checkpoint inhibitors-induced adrenal insufficiency.

Retrospective analysis of clinical characteristics and treatment of patients with immune checkpoint inhibitors-induced adrenal insufficiency.

Journal: Frontiers in oncology

Published: April 18, 2025

ARID1A deficiency attenuates the response to EGFR-TKI treatment in lung adenocarcinoma.

ARID1A deficiency attenuates the response to EGFR-TKI treatment in lung adenocarcinoma.

Journal: Frontiers in pharmacology

Published: February 23, 2025

Combination therapy with Chicoric acid and PD-1/PD-L1 blockade improves the immunotherapy response in patient-derived ovarian cancer xenograft model.

Combination therapy with Chicoric acid and PD-1/PD-L1 blockade improves the immunotherapy response in patient-derived ovarian cancer xenograft model.

Journal: Cell communication and signaling : CCS

Published: December 16, 2024

Showing 1-12 of 76

Last Updated: 09/26/2026